🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ StockGenie AI

HealthCare Global Enterprises Limited HCG NSEPHARMA

Healthcare · Medical Care Facilities · India
https://www.hcgoncology.com

HealthCare Global Enterprises Limited provides medical and healthcare services in India and internationally. The company offers cancer diagnostics services, including genomics and molecular diagnostics, digital PET, preventive oncology, physical examination, laboratory tests, home health services, digital pathology, and CTC detection; treatment services, such as medical oncology and haemato-oncology, radiation and surgical oncology, molecular imaging and theranostics, chemotherapy, robotic surgery, actinium and lutetium therapy, immunotherapy, psycho-oncology, targeted drug therapy, bone marrow transplant, pediatric oncology, organ preservation and reconstructive surgery, endocrine therapy, and liver transplant; and post care services comprising patient care, psychological support, nutrition and dietetics, multidisciplinary rehabilitation, and genetic counselling. It also provides cancer screening, interventional radiology, MRI, nephrology, clinical trial, hormone therapy, hematology, CAR T cell, translational and nuclear medicine, oncodermatology, anaesthesiology, paediatric and gynaecologic oncology, orthopaedic oncology, uro-oncology, infectious diseases, gastrointestinal and thoracic oncology, breast surgical oncology, clinical pharmacology, and pain and palliative services. In addition, the company operates multi-specialty hospitals under the HCG brand that offers inpatient and outpatient treatments with specialties in cardiology, neurology, orthopaedics, gastroenterology, urology, internal medicine and pulmonary, and critical care. Further, it provides oncology diagnostics services, including biomarker and translational research, and clinical research services under the Triesta Sciences brand; and fertility treatment services, including reproductive medicine, assisted reproduction, gynecological endoscopy, and fertility preservation under the Milann brand. HealthCare Global Enterprises Limited was founded in 1989 and is headquartered in Bengaluru, India.

READ MORE ›
₹637.25
+18.14% 1Y

Market & Price

Market Cap
₹9,514.28 Cr
Current Price
₹637.25
High / Low (52W)
₹776.30 / ₹521.75
Beta
-0.14

Valuation

Stock P/E
663.80
Industry PE
37.60
Forward P/E
44.49
PEG Ratio
-
Book Value
₹65.64
Price to Book
9.71
P/S
3.74
EV/EBITDA
22.52
Dividend Yield
-

Profitability & Returns

ROCE
7.00%
ROE
1.90%
ROA
3.71%
Profit Margin
0.54%
Op Margin
9.55%
EPS (Latest Qtr)
₹0.15
EPS (TTM)
₹0.96

Balance Sheet & Liquidity

Debt/Equity
1.23
Quick Ratio
0.94
Current Ratio
1.12
Debt
₹1,735.36 Cr
Total Assets
₹3,922.54 Cr
Current Assets
₹1,135.21 Cr
Working Capital
₹118.05 Cr

Ownership

Promoter Holding
70.64%
Chg in Prom Hold
-
FII / Inst Holding
16.43%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
₹10,491.56 Cr
Total Revenue (TTM)
₹2,545.41 Cr
EBITDA
₹465.79 Cr
Free Cash Flow
₹-122.50 Cr
Operating Cash Flow
₹347.10 Cr
Shares Outstanding
₹14.93 Cr
Gross Margin
36.36%
Payout Ratio
0.00%

Growth (CAGR)

Revenue 5Y
14.84%
Profit 5Y
-22.31%
Revenue (YoY)
11.50%
Earnings (YoY)
-71.20%

PROS

  • Compounding revenue at 14.8% over 5 years.

CONS

  • Trading at a high P/E of 663.8.
  • Earnings shrank at -22.3% CAGR over 5 years.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

NSE TradingView Screener.in

Fundamental Growth

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 HCG HealthCare Global Enterprises Limited NSEPHARMA 637.25 663.80 ₹9,514.28 Cr - 7.00% 1.90% 14.84% -22.31%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,799.20 37.59 ₹4.32 L Cr 0.92% 17.94% 14.72% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 6,667.00 68.97 ₹1.77 L Cr 0.45% 18.96% 16.19% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,410.80 68.96 ₹1.49 L Cr 0.86% 9.06% 16.98% 13.27% 20.21%
5 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,401.00 29.16 ₹1.13 L Cr 0.93% 14.88% 11.74% 7.23% 11.45%
6 DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA 1,303.50 25.90 ₹1.09 L Cr 0.61% 14.00% 11.83% 10.96% -2.35%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,077.70 21.51 ₹1.08 L Cr 0.09% 19.24% 18.32% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,267.70 19.49 ₹1.04 L Cr 0.53% 28.42% 26.91% 19.10% 131.46%
9 MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA 2,375.60 51.29 ₹98,090.71 Cr 0.08% 13.78% 12.45% 17.73% 14.28%
Ad space

Quarterly Results

Figures in INR.

Metric Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 583.43 Cr611.80 Cr645.16 Cr631.18 Cr650.29 Cr
Cost of Revenue 283.23 Cr294.89 Cr313.75 Cr315.69 Cr317.04 Cr
Gross Profit 300.20 Cr316.91 Cr331.41 Cr315.49 Cr333.25 Cr
Operating Expenses 252.55 Cr267.03 Cr270.90 Cr266.53 Cr270.98 Cr
Operating Income 47.65 Cr49.88 Cr60.51 Cr48.96 Cr62.27 Cr
EBITDA 115.86 Cr115.30 Cr126.24 Cr99.36 Cr106.76 Cr
Interest Expense 44.17 Cr45.47 Cr43.62 Cr44.78 Cr42.70 Cr
Pretax Income 13.62 Cr11.92 Cr19.82 Cr-6.07 Cr1.25 Cr
Tax Provision 6.85 Cr5.94 Cr-84.00 L1.83 Cr-2.79 Cr
Net Income 7.36 Cr4.75 Cr16.27 Cr-9.43 Cr2.17 Cr
Diluted EPS 0.520.341.15-0.680.15

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue -1,676.05 Cr1,889.91 Cr2,218.14 Cr2,538.43 Cr
Cost of Revenue -799.75 Cr909.99 Cr1,062.27 Cr1,241.37 Cr
Gross Profit -876.29 Cr979.92 Cr1,155.87 Cr1,297.06 Cr
Operating Expenses -708.04 Cr822.48 Cr979.93 Cr1,075.44 Cr
Operating Income -168.25 Cr157.44 Cr175.94 Cr221.62 Cr
EBITDA -302.75 Cr342.78 Cr422.86 Cr447.66 Cr
Interest Expense -94.39 Cr100.69 Cr154.56 Cr176.57 Cr
Pretax Income -44.88 Cr67.73 Cr56.96 Cr26.92 Cr
Tax Provision -27.25 Cr26.39 Cr8.13 Cr4.14 Cr
Net Income -29.35 Cr48.16 Cr44.41 Cr13.76 Cr
Diluted EPS -2.093.413.120.96

Compounded Sales Growth

5 Years:14.84%
1 Year:11.50%

Compounded Profit Growth

5 Years:-22.31%
1 Year:-71.20%

Stock Price Performance

1 Year:+18.14%
6 Months:-12.24%
3 Months:+9.66%
1 Month:+11.30%

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets -2,316.02 Cr2,707.50 Cr3,543.24 Cr3,922.54 Cr
Current Assets -580.34 Cr679.85 Cr843.80 Cr1,135.21 Cr
Cash & Equivalents -174.62 Cr272.61 Cr235.87 Cr536.05 Cr
Inventory -38.29 Cr42.67 Cr53.02 Cr59.82 Cr
Receivables -302.51 Cr294.03 Cr400.90 Cr420.70 Cr
Total Liabilities -1,446.60 Cr1,842.38 Cr2,553.19 Cr2,512.33 Cr
Current Liabilities -570.32 Cr743.71 Cr1,046.42 Cr1,017.16 Cr
Long Term Debt -361.74 Cr485.30 Cr604.58 Cr599.19 Cr
Total Debt -901.20 Cr1,274.36 Cr1,837.22 Cr1,735.36 Cr
Total Equity -860.52 Cr825.78 Cr922.44 Cr1,331.97 Cr
Shares Outstanding -14.00 Cr14.02 Cr14.03 Cr14.93 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow -251.59 Cr284.58 Cr317.11 Cr347.10 Cr
Investing Cash Flow --133.03 Cr-225.73 Cr-487.75 Cr-177.47 Cr
Financing Cash Flow --140.07 Cr-64.02 Cr-42.44 Cr240.67 Cr
Capital Expenditure --133.24 Cr-185.68 Cr-208.87 Cr-292.10 Cr
Free Cash Flow -118.35 Cr98.90 Cr108.24 Cr55.00 Cr
Net Change in Cash --21.51 Cr-5.16 Cr-213.08 Cr410.30 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % -52.3%51.9%52.1%51.1%
Operating Margin % -10.0%8.3%7.9%8.7%
Net Margin % -1.8%2.5%2.0%0.5%
ROE % -3.4%5.8%4.8%1.0%
ROCE % -9.6%8.0%7.0%7.6%

Shareholding Pattern

Insiders
70.64%
Institutions
16.43%
Public Float
55.98%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for HCG

No recent headlines available.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks